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Albumin modified by Amadori glucose adducts, formed in increased
amounts in diabetes, stimulates collagen IV production and gene expres-
sion in renal glomerular mesangial cells, and induces mesangial matrix
accumulation accompanied by increased mRNA encoding a1 (IV) colla-
gen and fibronectin in diabetic animals. These effects contribute to the
pathogenesis of diabetic nephropathy, and resemble biologic activities of
the cytokine TGF-b1, which also has been causally implicated in diabetic
renal disease. We postulated that Amadori-modified glycated albumin
modulates TGF-b1 expression in mesangial cells, and that TGF-b1 partic-
ipates in mediating the glycated albumin-induced increases in mesangial
cell matrix production. To test this hypothesis, we measured mRNA
encoding TGF-b1, the TGF-b Type II receptor and fibronectin, a key
matrix component of the TGF-b1 tissue response, after incubation of
mesangial cells with glycated albumin. Steady state levels of the mRNAs
encoding for these proteins were stimulated when mesangial cells were
cultured in the presence of albumin containing Amadori glucose adducts
compared with levels in cells cultured with the nonglycated, glucose-free
counterpart. The glycated protein-induced changes in mRNA expression
were observed with concentrations of glycated albumin encompassing
those found in clinical specimens and in media containing physiologic (5.5
mM) glucose concentrations, indicating that they were due to the glucose-
modified protein and not to a hyperglycemic milieu. Further, they were
accompanied by increased translated fibronectin protein, which was
prevented with TGF-b neutralizing antibody, as was the glycated albumin-
induced increase in fibronectin mRNA. The findings indicate that Ama-
dori-modified glycated albumin stimulates mesangial cell TGF-b1 gene
expression by mechanisms that are operative under normoglycemic con-
ditions. These data provide the first link between elevated glycated serum
albumin concentrations and increased TGF-b1 bioactivity in the patho-
genesis of mesangial matrix accumulation in diabetes.
The Diabetes Control and Complications Trial (DCCT) dem-
onstrated that improved glycemic control, evidenced by decreased
mean glycated hemoglobin levels, lowered the risk for develop-
ment of renal and other complications of diabetes [1]. These
results conclusively established hyperglycemia as an important
risk factor in diabetic nephropathy, although they did not define
mechanisms by which elevated glucose concentrations in diabetes
promote renal dysfunction. The recognition that hyperglycemia
accelerates nonenzymatic glycation, and that glucose-derived
modifications of proteins alter their structural and functional
properties, have implicated increased glycation as a mechanistic
link between hyperglycemia and the pathogenesis of microvascu-
lar disease in diabetes.
Nonenzymatic glycation is a condensation reaction between
glucose and reactive protein amino groups, yielding Schiff base
intermediates that undergo Amadori rearrangement to form
stable protein-glucose adducts [2–5]. In vivo, circulating glycated
proteins principally exist as Amadori products and their concen-
tration, driven by the ambient glucose concentration, is increased
in diabetes as a result of hyperglycemia [2, 3, 6–8]. Recently, we
have provided evidence strongly supporting a causal role for
elevated concentrations of glycated albumin in the development
of diabetic nephropathy, a disorder characterized pathologically
by an expansion of the renal glomerular mesangial matrix that
leads to an encroachment of cellular elements and a loss of
filtration area [9–12]. Serum containing concentrations of gly-
cated albumin that are found in diabetic subjects stimulates renal
glomerular mesangial cell production and gene expression of
Type IV collagen, the predominant constituent of the expanded
glomerular mesangial matrix that is seen in diabetes [13, 14].
Increased elaboration of Type IV collagen and increased mRNA
encoding for a1 (IV) collagen accompanied by decreased cell
replicative capacity and transcriptional activation of the a1 (IV)
collagen gene can be induced by incubation of mesangial cells with
purified glycated albumin in concentrations representing those
associated with diabetes [15, 16]. When diabetic db/db mutant
mice are treated with monoclonal antibodies (A717) that specif-
ically neutralize excess plasma concentrations of Amadori-modi-
fied glycated albumin, renal cortical overexpression of mRNAs
encoding a1 (IV) collagen and fibronectin is prevented, mesangial
matrix expansion is reduced, and changes reflecting compromised
renal function are improved [17–20]. These salutary effects are
independent of blood glucose concentration, and are not observed
in db/db mice treated with immunoglobulin that is not reactive
with glycated albumin.
The effects of glycated albumin on mesangial cell biology
resemble those of transforming growth factor-beta (TGF-b), a
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multifunctional cytokine polypeptide with potent fibrogenic activ-
ity [21–23]. TGF-b1 bioactivation is associated with the modula-
tion of cell growth and stimulation of collagen production by renal
tubular and glomerular mesangial cells in culture, and these
effects are prevented by TGF-b neutralizing antibodies [24–26].
Several investigators have reported that TGF-b1 mRNA is ele-
vated in kidneys of rodents with streptozotocin-induced insuli-
nopenic diabetes [27–30]. Such findings, and reports that serum,
urine and renal concentrations of the TGF-b protein are in-
creased in rodents with insulin-deficient diabetes [27, 29–31],
have helped foster the hypothesis that TGF-b1 plays a causative
role in diabetic renal disease. It has been postulated that matrix
overproduction leading to renal fibrosis evolves from increased
TGF-b1, initially induced as a reparative process in response to
tissue injury, but later representing chronic failure to terminate
tissue repair [32]. We and others have suggested that, in this
scenario, the stimulus triggering increased TGF-b1 in diabetes
may be elevated concentrations of glucose or angiotensin II, both
of which have been reported to induce TGF-b1 mRNA expression
in mesangial cells [24, 26, 33, 34]. However, the possibility that
glycated albumin influences TGF-b1 expression, or that TGF-b1
participates in mediating the glycated protein-induced increases
in mesangial cell matrix production, has not been examined.
The goal of the present experiments was to determine whether
glycated albumin modulates the TGF-b system in glomerular
mesangial cells. To this end, we examined the effect of glycated
albumin on steady state levels of mRNA encoding TGF-b1, the
Type II TGF-b receptor, and fibronectin, a key matrix component
of the TGF-b1 tissue response. We focused on the Type II
receptor because it is the primary signaling receptor that binds the
free ligand. The Type I receptor does not directly bind the free
ligand, and it is best described as the transducer [21]. Our
approach to these studies adhered to conditions in which the
glycated protein was represented by the Amadori modified con-
struct and not advanced glycation end products (AGE) [14, 35,
36]. Further, we examined effects in normal (5.5 mM) glucose
concentration to ensure that observed responses were due to the
glycated protein and not induced by elevated media glucose
concentration. We report that exposure of mesangial cells in
culture to glycated albumin in physiologic glucose concentration
stimulates gene expression of TGF-b1, the TGF-b Type II recep-
tor, and fibronectin, and the production of translated fibronectin
protein. The glycated albumin-induced stimulation of fibronectin
mRNA and protein were prevented in the presence of anti-TGF-b
neutralizing antibody.
METHODS
Cell culture
Murine mesangial cells in culture were derived from glomeruli
isolated from SJL/J mice with a graded sieving technique and
plated to explant [37, 38]. Mesangial cells were selected and
subcultured according to previously described criteria [37], includ-
ing morphology, ability to grow in medium containing D-valine
instead of L-valine, and the presence of cytoplasmic filaments
(desmin and vimentin), angiotensin II binding capacity, and
contractile response to angiotensin II. Cells were stabilized by
virus transformation with SV-40 and were carried in Dulbecco’s
modified Eagle’s medium (DMEM) containing 5.5 mM glucose
and 10% fetal calf serum (FCS). The suitability of transformed
mesangial cells and their parallelism with non-transformed cells
with respect to growth and response to media manipulations have
been documented [14, 25]. To initiate experiments under varying
culture conditions, mesangial cells were plated into 25 cm2 plastic
flasks, grown to confluence, rested for one day in serum-free
medium containing 5.5 mM glucose and then grown for 48 hours
in fresh media under experimental conditions described below.
Experimental culture conditions
The experimental conditions were initiated after the rest period
upon the addition of fresh media containing 5.5 mM glucose, 1%
FCS and purified glycated or nonglycated albumin (200 to 600
mg/ml), without or with TGF-b neutralizing antibody or irrelevant
immunoglobulin (30 mg/ml). Results of preliminary experiments
established that low concentrations of FCS maintained uniform
cell growth, but did not obscure responses induced by glycated
albumin or high glucose concentration. Glycated albumin was
added in concentrations representing those found in clinical
specimens, and encompassing those which previously have been
found to stimulate mesangial cell a1 (IV) collagen production,
mRNA expression and gene activation [8, 15, 16]. In nondiabetic
individuals the glycated form comprises approximately 1.0% of
serum albumin, and is equivalent to concentrations between 300
to 400 mg/ml of glycated albumin; the concentration of glycated
albumin is in this range or is increased 11⁄2- to threefold in diabetic
subjects, according to recent glycemic status [5, 8, 39]. Where
indicated, the experimental conditions employed 5% nonglycated
or glycated serum in place of the purified proteins, without or with
A717 monoclonal antibody (see below). For study of elaboration
of translated fibronectin, incubations under the various experi-
mental conditions were conducted in serum free media to ensure
that fibronectin measured in the post-incubation media repre-
sented that secreted by the cells.
Glycated protein preparation
Glycated albumin was prepared from albumin, purified from
human plasma by chromatography on Affi gel Blue and DEAE-
Sepharose, obtaining a homogeneous band of approximately
66,000 molecular weight on SDS gel electrophoresis. The glycated
protein was separated from the nonglycated protein by affinity
chromatography on phenylboronate agarose (PBA), which binds
Amadori adducts and not advanced glycation end products
(AGE). This protocol has been shown to yield glycated albumin
containing '1 mol glucose/mol albumin and reactive with the
A717 monoclonal antibody that specifically recognizes albumin
modified by Amadori glucose adducts and that does not react with
AGE-albumin [15–17]. The epitope defined by the A717 mono-
clonal antibody encompasses an albumin domain containing a
deoxyfructosyllysine residue and is structurally and immuno-
chemically distinct from those in AGE. The PBA pass-through,
used as source material for nonglycated albumin, contained ,
0.05 mol glucose/mol albumin, migrated on SDS-PAGE as a
single 66 kDa band, and did not react with the A717 monoclonal
antibody, as has been described [17].
Glycated serum was prepared by incubating sterile-filtered
normal human serum for four days at 25°C with 28 mM glucose in
phosphate buffered saline (PBS), followed by dialysis against PBS
to remove free glucose and again sterile-filtering. Serum incu-
bated for the same period in PBS without glucose, dialyzed and
sterile filtered, was used as control (normal serum; NS). The
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glycated serum (GS) contained diabetic concentrations of gly-
cated albumin, which were approximately twofold those in normal
serum when measured by enzyme-linked immunoassay using the
murine monoclonal antibody that specifically recognizes deoxy-
fructosyllysine epitopes in albumin modified by Amadori glucose
adducts [8, 17, 39]. Albumin, the principal serum protein, contrib-
utes 80 to 90% of the total glycated serum protein concentration.
Antibody preparation
A717 was harvested from ascitic fluid of mice injected with the
A717 cell line, purified by affinity chromatography on Protein G,
and digested with papain to produce Fab fragments. Specificity
and reactivity of the Fab fragments with the glycated albumin
epitope was confirmed as described [18, 19]. Affinity purified
murine IgG, unreactive with glycated albumin or other serum
proteins, was used as control.
The TGF-b antibody was a neutralizing mouse monoclonal
antibody kindly provided by Dr. B. Fendly (Genentech, S. San
Francisco, CA, USA). This antibody (2G7; IgG2b k) is panselec-
tive against all mammalian isoforms of TGF-b (b1, b2, b3). The
concentration employed (30 mg/ml) neutralizes more than 80% of
the TGF-b bioactivity determined by the mink lung epithelial
bioassay [40]. This antibody also has been shown to prevent early
features of diabetic renal disease in streptozotocin-diabetic mice
[30]. An irrelevant isotype-matched murine immunoglobulin
(HP6001; ATCC, Rockland, MD, USA) was used as control.
RNA hybridization analysis
RNA was extracted from mesangial cells harvested after culture
under the described conditions and hybridized with 32P-labeled
cDNA probes as previously described [14, 41]. Cells were dena-
tured in 4 M guanidinium thiocyanate, 25 mM sodium citrate pH
7.0, 0.5% sarcosyl and 0.1 M 2-mercaptoethanol. Twenty to 30 mg
of total RNA were electrophoresed on a 1.2% agarose gel,
transferred onto nylon membranes, and ultraviolet wave cross-
linked. Integrity and equal loading of samples were assessed by
methylene blue staining of the transferred RNA. The membranes
were hybridized with labeled cDNA inserts (32P-deoxycytidine
59-triphosphate; Amersham) using random priming. After hybrid-
ization, blots were washed for 30 minutes in 2 3 SSC with 0.1%
SDS at 62°C, followed by two washes of 15 minutes in 0.1 3 SSC
with 0.1% SDS at 62°C. The membranes were autoradiographed
with intensifying screens at 270°C for up to 10 days. Blots were
then stripped for two hours at 62°C with 5 mM Tris, 0.2 mM EDTA
(pH 8.0), and 5% sodium pyrophosphate, and subsequently
rehybridized with cDNA fragment encoding an RNA standard to
account for small variations in RNA loading and transfer. The
loading standards employed were GAPDH mRNA and mRNA
encoding for mouse ribosomal protein L32 (mrpL32) [42]. Ex-
posed films were scanned with a laser densitometer, and mRNA
levels were calculated relative to those of the loading standard.
The cDNA probes encoding murine TGF-b1 and the TGF-b
Type II receptor were first synthesized by the polymerase chain
reaction (PCR) using murine kidney cDNA as template and
specific oligonucleotide primers based on the published cDNA
sequences [43–45]. The PCR products were cloned into the
pCRII TA cloning system (Invitrogen, LaJolla, CA, USA). Nu-
cleotide sequencing of the PCR products confirmed identity of the
probes. The cDNA probe for fibronectin was a 649 nucleotide
AvaI/HindIII fragment that codes for most of the human fibronec-
tin 39 untranslated regions [46], specifically hybridizes with 8.8 kb
fibronectin mRNA, and recognizes mouse and rat fibronectin.
Analysis of translated proteins
Fibronectin in the media collected at the end of the experimen-
tal period was measured by an ELISA (Exocell, Philadelphia, PA,
USA), in which fibronectin in standard or sample was bound to
gelatin that had been immobilized onto microtiter wells, and was
detected with HRP-conjugated monoclonal antibody against fi-
bronectin [47].
RESULTS
Initial experiments examined the ability of glycated serum to
stimulate mesangial cell gene expression of TGF-b1 and fibronec-
tin, using cultures of mesangial cells made quiescent by serum
deprivation for one day and then treated for 48 hours with media
made 5% in NS or GS. The media glucose concentration in these
studies was 5.5 mM. On Northern blot analysis, cells grown in
media supplemented with GS expressed higher levels of TGF-b1
and fibronectin mRNA than did cells grown in media supple-
mented with NS (Fig. 1). Densitometric scanning of the exposed
films with normalization in relation to the GAPDH loading
standard confirmed that steady state levels of TGF-b1 and fi-
bronectin mRNA were increased in cells exposed to GS compared
with levels in cells cultured with NS; the TGF-b1:GAPDH mRNA
relative ratio was 1.34 and the fibronectin:GAPDH relative ratio
Fig. 1. Transforming growth factor-beta1
(TGF-b1) and fibronectin gene expression in
mesangial cells cultured for 48 hours in media
containing 5.5 mM glucose and 5% normal (NS)
or glycated (GS) serum. Representative
Northern blots from two experiments are
shown.
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was 2.77, where the ratios in cells cultured with NS were assigned
arbitrary values of 1.0. Blocking experiments with the A717
monoclonal antibody indicated that the increased fibronectin
mRNA induced by glycated serum largely derived from glycated
albumin, which represents '80% of glycated serum proteins. The
steady state level of mRNA encoding fibronectin in cells cultured
with glycated serum in the presence of A717 was significantly
lower than that in cells cultured with GS in the absence of A717
(Fig. 2), giving a relative ratio compared with NS of 1.2. A717 did
not affect fibronectin mRNA in cells incubated with normal serum
(not shown).
Corroboration that glycated albumin in the glycated serum
stimulated the TGF-b system was obtained by supplementing cell
cultures with purified glycated versus nonglycated albumin (200 to
600 mg/ml) in media containing 1% FCS and physiologic (5.5 mM)
glucose concentration, and examining mesangial cell levels of
mRNA encoding for fibronectin, TGF-b1, and the TGF-b Type II
receptor. Northern blot analysis revealed that the steady state
levels of mRNA encoding for these three proteins were increased
after incubation with glycated albumin compared with levels in
control incubations supplemented with nonglycated albumin (Fig.
3). With 200 mg/ml glycated albumin, the respective relative ratios
of mRNA to that of the loading standard were 2.13 for fibronec-
tin, 2.23 for TGF-b1, and 1.83 for TGF-b Type II receptor.
Further increases in the relative ratios were observed with higher
concentrations (600 mg/ml) of glycated albumin (Table 1).
The glycated albumin-induced increases in mRNAs encoding
for these proteins were comparable to those observed when
mesangial cells were cultured for 48 hours in the presence of a
hyperglycemic milieu. Figure 4 depicts representative mRNA
hybridization assays for fibronectin, TGF-b1 and TGF-b Type II
receptor in cells incubated in media containing 1% FCS, 600
mg/ml nonglycated or glycated albumin, and 5.5 mM versus 25 mM
glucose. In cells supplemented with nonglycated albumin, relative
ratios (mRNA:loading standard) in cells cultured in 25 mM
glucose compared with those in cells cultured in 5.5 mM glucose
were 3.38 for fibronectin, 2.77 for TGF-b1 and 2.38 for TGF-b
Type II receptor. Twenty-five mM glucose also augmented the
glycated albumin-induced increases in TGF-b1 and fibronectin
steady-state mRNA levels relative to those observed in 5.5 mM
glucose concentration, giving an additive effect on gene expres-
sion of TGF-b1 but not fibronectin (Table 2).
The stimulated fibronectin gene expression induced by glycated
albumin under normoglycemic conditions was accompanied by
increases in the translated protein, measured by ELISA (Table 3).
Fig. 2. Fibronectin gene expression in mesangial cells cultured for 48
hours in media containing 5.5 mM glucose and 5% normal (NS, lane 1) or
glycated serum (GS, lanes 2 and 3). Cells were cultured in the presence of
murine immunoglobulin unreactive with glycated albumin or other serum
proteins (lanes 1 and 2) or with A717 anti-glycated albumin monoclonal
antibody (lane 3). Representative Northern blots from two experiments
are shown.
Fig. 3. RNA hybridization analysis of mRNA encoding fibronectin, trans-
forming growth factor beta1 (TGF-b1), and TGF-b Type II receptor
(TbIIR) in mesangial cells cultured for 48 hours with nonglycated (NA)
or glycated (GA) albumin in 5.5 mM glucose and 1% FCS. Representative
Northern blots from three experiments are depicted.
Table 1. Glycated albumin effects on mesangial cell mRNA
Supplement Fibronectin TGF-b1
TGF-b Type II
receptor
Nonglycated albumin
600 mg/ml
1.0 1.0 1.0
Glycated albumin
200 mg/ml
2.13 2.23 1.83
Glycated albumin
600 mg/ml
2.28 2.60 2.34
Mesangial cells were cultured for 48 hours in DMEM containing 5.5 mM
glucose, 1% FCS, and the indicated concentrations of nonglycated or
glycated albumin. Data were obtained by densitometric scanning of
autoradiographs of the hybridization assays performed with the corre-
sponding cDNAs and with the mrpL32 cDNA probe. Values represent
relative ratios compared with those in cells incubated with nonglycated
albumin, assigned an arbitrary value of 1.0. Abbreviation TGF-b1 is
transforming growth factor-beta1.
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Fibronectin concentrations in cultures supplemented with non-
glycated albumin did not differ significantly from those in media
from cells cultured in unsupplemented media. However, fibronec-
tin concentrations in media from cells cultured with glycated
albumin were significantly increased compared with unsupple-
mented and nonglycated albumin-supplemented incubations. In-
clusion of TGF-b antibody in culture media largely prevented the
glycated albumin-induced increase in fibronectin, indicating that
TGF-b participates in mediating this response.
Confirmation that TGF-b participated in the glycated albumin-
induced stimulation of fibronectin gene expression under normo-
glycemic conditions was sought by Northern blot analysis after
incubation of cells with glycated albumin in the presence of
TGF-b neutralizing antibody. Figure 5 shows that anti-TGF-b
prevented increased fibronectin mRNA in cells cultured with
glycated albumin. On densitometric scanning, the relative fi-
bronectin:GAPDH ratio compared with that for nonglycated
albumin was 1.60 for glycated albumin and 0.91 for glycated
albumin plus anti-TGF-b antibody. The relative ratio in cells
incubated with 25 mM glucose, shown in Figure 5 and evaluated
for comparative purposes, was 2.27. An isotype-matched immu-
noglobulin did not reduce fibronectin mRNA in cells cultured
with glycated albumin (not shown).
DISCUSSION
The results presented in these experiments demonstrate that
glycated albumin induces coordinate increases in mRNA encod-
ing for TGF-b1, the TGF-b Type II receptor and fibronectin in
renal glomerular mesangial cells. These findings provide evidence
linking increased TGF-b1 gene expression to the glycated albu-
min-induced increases in extracellular matrix protein and mRNA
synthesis that have been observed in glomerular mesangial cells in
Fig. 4. Effect of high glucose concentration on mesangial cell gene
expression of fibronectin, transforming growth factor-b1 (TGF-b1), and
TGF-b Type II receptor (TbIIR). Mesangial cells were cultured for 48
hours in media containing 1% FCS, 600 mg/ml nonglycated (NA) or
glycated (GA) albumin, and 5.5 versus 25 mM glucose. Representative
Northern blots from three experiments are depicted.
Fig. 5. Effect of neutralizing transforming growth factor-b (TGF-b)
antibody on mesangial cell gene expression of fibronectin. Cells cultured
for 48 hours in media containing 1% FCS, 5.5 mM glucose, 400 mg/ml
nonglycated (NA) or glycated (GA) albumin with anti-TGF-b (aT).
Northern blot analysis of mRNA from cells incubated with high (25 mM)
glucose media is shown for comparative purposes.
Table 2. Glucose effects on mesangial cell mRNA
Supplement Glucose Fibronectin TGF-b1
TGF-b Type II
receptor
NA 5.5 mM 1.0 1.0 1.0
NA 25 mM 3.38 2.77 2.38
GA 5.5 mM 2.28 2.60 2.34
GA 25 mM 3.41 3.63 2.32
Mesangial cells were cultured for 48 hours in DMEM containing 5.5 or
25 mM glucose, 1% FCS, and 600 mg/ml of nonglycated (NA) or glycated
(GA) albumin. Data are expressed as described in the legend to Table 1.
Table 3. Effect of TGF-b antibody on fibronectin production by
glomerular mesangial cells
Supplement Antibody
Fibronectin
ng/ml
None — 514 6 106
Nonglycated albumin — 512 6 112
Glycated albumin — 2330 6 121a
Glycated albumin MIg 2024 6 125a
Glycated albumin Anti-TGF-b 1382 6 94ab
Results represent mean 6 SEM of four independent cultures in each of
which media were collected after incubation for 48 hours with 600 mg/ml
of nonglycated versus glycated albumin and 30 mg/ml of isotype-matched
irrevelant murine immunoglobulin (MIg) or neutralizing TGF-b murine
monoclonal antibody.
a P , 0.05 compared with nonglycated albumin.
b P , 0.05 compared with no antibody or with MIg.
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vitro and in renal cortex of diabetic animals in vivo [9, 14–16, 18,
19]. High media glucose concentration has also been shown to
stimulate gene expression of a1 (IV) collagen, fibronectin, and
TGF-b1 in cultured mesangial cells [26, 48–50]. This stimulation
is accompanied by activation of protein kinase C, transient
elevation of mRNA levels of c-fos and c-jun oncogenes and
corresponding increases in c-fos and c-jun proteins, and delayed
growth inhibition in association with bioactivation of TGF-b1 [25,
51–53]. Additionally, high glucose-induced increases in TGF-b
are believed to involve protein kinase C signaling [54, 55].
Increased TGF-b1 therefore appears to be an important mediator
of hyperglycemia with respect to the influence of elevated glucose
concentrations on the elaboration and expression of mRNAs
encoding for matrix macromolecules. However, in the present
experiments increased levels of mRNA encoding for TGF-b1 and
fibronectin in response to glycated albumin were observed in low
physiologic glucose concentration (5.5 mM), and cannot be as-
cribed to an effect of high glucose in the culture media.
The findings reported herein are the first to demonstrate that
purified albumin modified by Amadori glucose adducts modulates
TGF-b1 expression in mesangial cells, and that TGF-b1 partici-
pates in mediating glycated albumin-induced changes in mesan-
gial matrix production. These observations afford new insight into
the increased TGF-b1 gene expression and TGF-b1 protein
content that have been observed in kidneys of diabetic animals,
and suggest a dual-pronged mechanism linking glucose, glycated
albumin, and TGF-b1 to the development of glomerular matrix
accumulation in diabetes [27, 28, 32]. Increased glomerular TGF-
b1, which can be induced by either elevated glucose or glycated
albumin, stimulates the production and gene expression of the
extracellular matrix macromolecules fibronectin and Type IV
collagen. Hyperglycemia is the driving force for increased albumin
glycation, but the effects of glycated albumin do not require a
hyperglycemic milieu to be operative. Extrapolated to the in vivo
situation, this means that the influence of glycated albumin, which
has a circulating half life of about two weeks, on the TGF-b
system can continue after restoration of normoglycemia and can
act independently of hyperglycemia.
The observation that glycated albumin increased gene expres-
sion of the primary signal-transducing TGF-b Type II receptor
deserves comment. Although up-regulation of the receptor could
be a consequence of a decrease in the concentration of the
TGF-b1 ligand [56], TGF-b1 expression actually was stimulated by
glycated albumin. Since TGF-b1 participates in a positive feed-
back loop that auto-stimulates TGF-b1 expression [57], a decrease
in translated TGF-b1 protein would be unlikely. Indeed, the
decreased fibronectin production in response to the neutralizing
anti-TGF-b antibody indicates that TGF-b protein bioactivity was
increased in conditioned media when cells were incubated with
glycated albumin. Moreover, experiments with cultured mesangial
cells and in streptozotocin-diabetic rodents suggest that hypergly-
cemia can stimulate TGF-b Type II receptor expression indepen-
dently of ligand concentration [30, 58, 59]. Elevated media glucose
concentration increases Type II receptor mRNA and protein, as
assessed by Western blot and by 125I-TGF-b1 binding studies [58,
59]. The results of our studies indicate that glycated albumin may
also exert a direct influence on TGF-b Type II receptor expres-
sion.
The demonstration of a relationship between glycated albumin
and the TGF-b system is in keeping with the previously reported
importance of these factors in the pathogenesis of diabetic renal
disease [18, 19, 30]. The present observations extend the recent in
vivo studies in which we demonstrated that treatment directed
against glycated albumin or TGF-b has a salutary influence on
renal pathobiology in diabetes. Chronic treatment of db/db mice
with anti-glycated albumin monoclonal antibodies ameliorates the
cell biology, histomorphometric and functional changes of dia-
betic nephropathy in this model [18–20]. Short-term treatment of
streptozotocin-diabetic mice with neutralizing antibodies directed
against TGF-b reduces kidney weight and glomerular hypertro-
phy, and attenuates the increase in extracellular matrix mRNA
levels [30].
It will be interesting to examine whether glucose and glycated
albumin activate TGF-b1 expression in mesangial cells through a
common mechanism, such as protein kinase C signaling [54, 55,
60]. Although the mechanism by which glycated albumin stimu-
lates TGF-b1 gene expression is speculative, it is possible that
increased electronegativity of albumin from glycation of lysine
amino groups enhances TGF-b1 retention in the pericellular
milieu and/or confers proteoglycan-like properties that mimic
Type III betaglycan receptor activity, which serves to anchor
TGF-b1 in the pericellular environment and present it to other
receptors [21, 22, 61–64]. It is also possible that occupancy or
modulation of low affinity TGF-b receptors by glycated albumin
impedes termination of TGF-b1 receptor-mediated events. Gly-
cated albumin may additionally stimulate matrix production
through mechanisms unrelated to TGF-b1, as has been suggested
by the identification of a cell associated ligand-receptor system for
the Amadori-modified protein [65–67]. This possibility is sup-
ported by the finding that anti-TGFb antibody significantly re-
duced but did not completely correct the glycated albumin-
induced increase in fibronectin production (Table 3).
In summary, we have shown that albumin modified by Amadori
glucose adducts stimulates the gene expression of TGF-b1, the
TGF-b Type II receptor and fibronectin by murine mesangial cells
in culture. These effects are observed in physiologic glucose
concentration. The findings link increased glycated albumin in
diabetes to increased TGF-b1 bioactivity in the pathogenesis of
glomerular mesangial matrix accumulation.
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